Company intelligence / Profile preview
T-Cell Bioscience
Beijing, Beijing, China
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
01
Overview
T-Cell Bioscience is a clinical-stage biotechnology company focused on developing T cell receptor engineered T cell (TCR-T) therapies for solid tumors. Its lead program, TC-E20, targeting HPV16 E7, has advanced into Phase 1/2 clinical trials for cervical and other HPV-positive cancers, showing manageable safety and preliminary anti-tumor activity.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyT cell receptor engineered T cell therapyCAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Peking University Cancer Hospital
Beyond the preview
Go deeper on T-Cell Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T-Cell Bioscience.